Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary product candidates for individuals suffering from central nervous system disorders. The company’s principal development pipeline centers on roluperidone, an investigational therapy designed to target negative symptoms in patients diagnosed with schizophrenia. As a development-stage biopharmaceutical organization, its prospective customer base encompasses healthcare providers, medical facilities, and the broader patient population requiring treatment for central nervous system indications.

The company operates as a single reporting segment without commercial product sales, commercial distribution channels, or dedicated marketing and sales infrastructure. In terms of geographical presence, its clinical development programs involve patient recruitment across clinical trial sites situated in the United States and international locations. Minerva Neurosciences maintains its corporate headquarters and principal executive offices in Burlington, Massachusetts.

Summary of the business section of Minerva Neurosciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 7 full-time employees.”